Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Cardiovasc Revasc Med ; 18(1): 16-21, 2017.
Article in English | MEDLINE | ID: mdl-27866748

ABSTRACT

BACKGROUND/PURPOSE: Drug-eluting stents (DES) reduce in-stent restenosis and repeat revascularization in comparison to bare metal stents. Individual DES vary, however, in regard to rates of restenosis and stent thrombosis; they also differ in regard to their platform and physical characteristics. The Promus Premier was designed to improve the performance of the Promus Element, with respect to conformability, trackability, and avoidance of longitudinal stent deformation; there is little published data, however, on clinical outcomes with Promus Premier. METHODS: We performed a registry study that compared 952 patients who underwent percutaneous coronary intervention with Promus Premier to 595 patients who received Taxus Liberte and 600 patients who received Xience V for a variety of indications. The primary endpoint was a composite of all-cause mortality, definite or probable stent thrombosis, myocardial infarction, and target vessel revascularization (TVR-MACE). Kaplan-Meier analysis and Cox proportional hazards regression were performed in order to compare the three stents in regard to outcomes at 1year. RESULTS: Procedural success was highest with Premier (99.4%) when compared to Xience V (98.0%) and Taxus Liberte (97.3%; p<0.001). Unadjusted survival analysis showed that TVR-MACE was less frequent with Premier in comparison to Taxus Liberte (p=0.003), and similar frequency in comparison to Xience V (p=0.16). Following multivariable adjustment, and using Xience V as the reference, there was only a borderline association of Promus Premier and lower rates of TVR-MACE (HR 0.69, 95% CI 0.45-1.04; p=0.075). CONCLUSION: Promus Premier demonstrates excellent procedural success rates and real-world outcomes that are similar to Xience V.


Subject(s)
Coronary Artery Disease/therapy , Drug-Eluting Stents , Percutaneous Coronary Intervention/instrumentation , Aged , Cardiovascular Agents/administration & dosage , Chi-Square Distribution , Coronary Artery Disease/diagnostic imaging , Coronary Thrombosis/etiology , Everolimus/administration & dosage , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Multivariate Analysis , Myocardial Infarction/etiology , Percutaneous Coronary Intervention/adverse effects , Proportional Hazards Models , Prosthesis Design , Registries , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...